Decompensated Heart Failure in Acute Care
Page Summary
- Acute decompensated heart failure (ADHF) is a sudden or gradual worsening of heart failure signs and symptoms needing urgent therapy, most commonly with pulmonary or systemic fluid overload and raised intracardiac filling pressures.
- Haemodynamic profile guides safe activity: warm and wet patients (perfused but congested) generally tolerate progressive mobility alongside diuresis, while cold and wet patients are higher risk and mobilisation is often contraindicated.
- Physiotherapists dose early mobilisation with Borg dyspnoea or rating of perceived exertion (RPE), with an early ceiling of about 3-5 out of 10, and never rely on heart rate alone.
- Outcome measures include gait speed (below 0.8 m/s suggests higher risk), 5x sit-to-stand, Short Physical Performance Battery and 6-minute walk test (minimal clinically important difference roughly 30 m).
Original Editor - Ewa Jaraczewska based on the course by Katelyn Whitlock
Top Contributors - Ewa Jaraczewska
Introduction
Acute decompensated heart failure (ADHF) is a sudden or gradual worsening of heart failure's (HF) signs and symptoms requiring urgent therapy. It is most commonly characterised by pulmonary or systemic fluid overload and elevated intracardiac filling pressures. This reading page outlines essential background on epidemiology, pathophysiology, and clinical classification, followed by practical guidance on inpatient assessment, medication considerations, early mobilisation strategies, and standardised outcome measures.
Heart Failure
Epidemiology and Aetiology
Heart failure affects an estimated 64 million people worldwide.[1] Prevalence is 1-2% of adults in high-income countries and rises above 10% after age 70. [2] It is among the most common causes of unplanned admission in older adults. About half of cases are now heart failure with preserved ejection fraction (HFpEF), a share growing with population ageing, obesity and diabetes. [3]
Thirty-day hospital readmission is approximately 20-25%, and one-year mortality is commonly reported at 20-30%. Each admission tends to leave the patient with a lower functional baseline. [4] Underlying causes include ischaemic heart disease, hypertension, diabetes, valvular disease, cardiomyopathy, atrial fibrillation, chronic kidney disease and cardiotoxic therapies. [5] Decompensation is usually precipitated by non-adherence to medication or sodium restriction, infection, ischaemia, arrhythmia, uncontrolled hypertension, anaemia, renal deterioration or NSAID use, although no trigger is found in a sizeable minority of admissions.[6]
Classification
Ejection Fraction

Ejection fraction (EF) remains the primary classification:
- EF 40% or lower defines heart failure with reduced ejection fraction (HFrEF), or systolic heart failure. [7]
- EF 41% to 49% describes heart failure with mildly reduced ejection fraction (HFmrEF), which is also termed HF with mid-range EF. [8]
- EF equal or greater than 50% describes heart failure with preserved ejection fraction (HFpEF), which presents with objective evidence of raised filling pressures. [9]
- Heart failure with improved ejection fraction (HFimpEF) describes a heart failure in which a previously reduced EF has recovered, and treatment should usually continue. EF was typically at or below 40% and has since improved by at least 10% to reach above 40%.[10]
Severity
Severity is another HF classification. The American College of Cardiology and American Heart Association (ACC/AHA) classifies HF into stages A-D, which track progression from risk to refractory disease. The New York Heart Association Functional Classification (NYHA) classifies HF into class I-IV. NYHA class is subjective and varies day to day, so the medical team must document the specific activity that provokes symptoms:[11]

- Class I — Unrestricted activity: typical daily physical activities do not provoke unwarranted fatigue, breathlessness, or palpitations.
- Class II — Mild Restriction: asymptomatic and comfortable while resting, though routine physical exertion induces fatigue, shortness of breath, or cardiac palpitations.
- Class III — Moderate-to-Severe Restriction: comfortable at rest, but minor or sub-ordinary exertion (such as dressing oneself or walking minimal distances) triggers symptomatic distress.
- Class IV — Severe Restriction: inability to perform any level of physical activity without discomfort; symptoms of heart failure are present even during complete rest.
Haemodynamic Profile

In acute settings, evaluating a patient’s haemodynamic profile offers a practical framework to determine safe activity levels. [12] This clinical assessment relies on two key parameters measured at the bedside: perfusion (warm versus cold) and congestion (dry versus wet):[13]
- Warm and wet (perfused but congested): The most frequent profile; these patients generally tolerate progressive mobility alongside diuresis therapy.
- Cold and wet (hypoperfused and congested): A higher-risk group that may require inotropic support, for whom physical mobilisation is often contraindicated.
- Dry profiles: Considerably less common in acute clinical practice.
Accurately establishing this profile provides essential guidance on appropriate clinical expectations and exercise tolerance for each patient.
Pathological process
In HFrEF, the left ventricle becomes too weak to squeeze effectively, leaving it unable to pump adequate amounts of blood throughout the body. Reduced contractility lowers cardiac output and triggers sympathetic and renin-angiotensin-aldosterone activation. This produces sodium and water retention, vasoconstriction and adverse remodelling. [7]
In HFpEF, impaired relaxation and reduced compliance mean filling pressures rise steeply with small changes in volume or heart rate. Although the left ventricle squeezes and pumps normally, stiffness or scarring prevents the heart muscle from relaxing properly between beats. Consequently, the heart cannot fill with sufficient blood, leading to fluid and blood backing up into the body and lungs.[9] Tachycardia shortens diastole and worsens filling, which is why atrial fibrillation is so poorly tolerated. Haemodynamic congestion often precedes clinical congestion by days, and fluid redistribution, not only fluid gain, can produce symptoms without weight change.
Clinical note: Exercise intolerance in HF is not purely cardiac. Skeletal muscle atrophy, impaired oxidative capacity, endothelial dysfunction, chronotropic incompetence, inspiratory muscle weakness, anaemia, iron deficiency and hospital-acquired deconditioning all contribute. These peripheral factors are the most trainable, and they explain why function often lags behind haemodynamic recovery.[14]
Acute Decompensated Heart Failure
In the acute decompensated heart failure it helps to recognise the patient's stage in the decongestion pathway. During active congestion, work of breathing is high and reserve is limited, so the focus is positioning, energy conservation and very short bouts. During brisk diuresis, fluid shifts quickly, and orthostatic hypotension, cramps, electrolyte disturbance and rising creatinine become the main risks. Therapy is best timed around diuretic peaks and toileting. Near euvolaemia, which is "a state of normal or adequately controlled body fluid volume with no clinically significant fluid overload or congestion," [15] deconditioning rather than congestion is the main barrier, and intensity and complexity can be progressed.
Clinical presentation
Congestion presents as dyspnoea, orthopnoea, paroxysmal nocturnal dyspnoea, oedema, raised jugular venous pressure, hepatomegaly, crackles, effusions and early satiety.[16] Hypoperfusion presents as cool peripheries, narrow pulse pressure, confusion, oliguria, hypotension and rising creatinine or lactate. [17]
Older adults frequently present atypically, with fatigue, delirium, anorexia, falls or functional decline rather than classic breathlessness. [18] Crackles may be absent in chronic HF because of lymphatic adaptation, and dyspnoea can be disproportionate to SpO₂, so use symptom scales alongside oximetry. [19]
Multimorbidity such as Chronic Obstructive Pulmonary Disease (COPD), anaemia, kidney disease, frailty and cognitive impairment shapes mobility decisions as much as the HF itself.[20]
Diagnostic tests
Diagnostic testing in heart failure aims to confirm the diagnosis, identify underlying etiology, assess severity, and guide therapeutic decisions. A comprehensive evaluation integrates clinical presentation with laboratory assays, non-invasive imaging, and electrical monitoring to provide a complete hemodynamic and structural assessment:[21]
- Natriuretic peptides (BNP and NT-proBNP) have strong rule-out value and moderate rule-in value. Levels rise with age, atrial fibrillation and renal impairment and are lower in obesity, so a normal result in an obese patient is less reassuring. Falling values during admission suggest effective decongestion.
- Echocardiography describes EF, diastolic grade, atrial size, valve disease, pulmonary artery pressure and right ventricular function. ECG and telemetry assess rhythm, ischaemia and conduction.
- Troponin excludes acute coronary syndrome, although chronic low-level elevation is common in HF.
- Chest radiography and lung ultrasound show vascular congestion, effusions and B-lines.
- Blood tests cover renal function, electrolytes, full blood count, iron studies, liver and thyroid function, and HbA1c.
- Invasive haemodynamic monitoring is reserved for unclear or refractory cases.
Red Flags
Warning signs of a failing trajectory include diuretic resistance, rising creatinine, worsening hypotension, new cool extremities, rising lactate, escalating oxygen need or deterioration after initial improvement. A decline in function is often the first sign and should be communicated early. [22]
Common Medications for ADHF
| Medication class | Purpose |
|---|---|
| Loop diuretics | Decongestion |
| Mineralocorticoid receptor antagonists (MRAs) / thiazides | Add-on diuresis; MRAs improve outcomes in HFrEF |
| Angiotensin-Converting Enzyme Inhibitors (ACEi) / Angiotensin II Receptor Blockers (ARB) / Angiotensin Receptor-Neprilysin Inhibitor (ARNI) | Afterload reduction, remodelling |
| Beta-blockers | Rate control, outcomes in HFrEF |
| Sodium-glucose transport protein 2 (SGLT2) inhibitors | Fewer HF hospitalisations |
| IV nitrates | Symptom relief |
| Inotropes | Low-output states |
| Digoxin | Rate control |
Clinical note: Dizziness after a new medication or dose change should be treated as a medication effect until proven otherwise.
Acute Care Physiotherapy Assessment in ADHF
Beyond diagnosis and vital signs, the chart should inform the treating clinician whether decongestion is on track. [24] They must look at admission weight, daily weights, net fluid balance and urine output. Physiotherapist should review haemodynamic support, since inotropes, vasopressors or recent titration of IV vasodilators are reasons to defer or modify mobility. [25] They need to check telemetry for new or paroxysmal arrhythmia, ectopy and pauses, and trend potassium, magnesium, creatinine, sodium, haemoglobin and lactate. It is important to take a note about devices and planned procedures, including defibrillators, pacemakers, mechanical circulatory support, angiography and cardioversion, because shock thresholds and device restrictions affect exercise intensity. [26]
Treatment goals must be established, since palliative or advanced HF pathways change how good progress is defined. When formulating goals, physiotherapists must consider the patient's pre-admission function, cognition, frailty and social context.[27]
During the assessment, clinician should use local early mobilisation criteria for hold parameters. As a general guide, they must defer or stop activity for new chest pain, symptomatic hypotension, a rapidly rising oxygen requirement, unstable arrhythmia, new neurological signs or marked symptom escalation. Hypotension treshold should be interpreted in context, because many people with chronic HF have low baseline blood pressure.[28]
Acute Care Physiotherapy Treatment in ADHF
Early mobilisation is generally safe and beneficial once the patient is haemodynamically stable. Inactivity accelerates muscle loss, so short frequent bouts are preferred to single long sessions. Mobility should be dosed using Borg dyspnoea or Rate of Perceived Exertion (RPE), with an early ceiling of about 3-5 out of 10, alongside the talk test, recovery time and trends in vital signs. Physiotherapist should never rely on heart rate alone. They must monitor SpO₂, blood pressure, heart rate and rhythm where telemetry is available, and check the orthostatic response after diuresis.[28]
Upright or supported forward-lean positions reduce work of breathing. Pursed-lip and paced breathing and planned rests are symptom-management tools and do not treat oedema. Functional training may include repeated sit-to-stand, graded walking, stairs when required for discharge and low-load resistance training of large muscle groups. Inspiratory muscle training once stable are good adjuncts. [29] Coordinated walking programmes with nursing, screennig for delirium and malnutrition, and involving dietitians, pharmacists and HF nurses are important aspects of multidisciplinary treartment approach in ADHF.[30]
Education should begin early and cover daily weights, symptom diaries, pacing, and sodium and medication adherence. Clinician should teach patients and carers when to seek help, which is commonly recommended with a gain of more than 2 kg over three days or worsening breathlessness or swelling. [31] Physiotherapist should be involved with referring the patient to cardiac rehabilitation or an HF exercise programme, which reduces hospitalisation and improves quality of life. Where frailty, cognitive impairment or limited support is present, they might consider early post-discharge physiotherapy or short-term rehabilitation.
Clinical note: The patient's readiness for discharge is more than function. The patient should reach near-euvolaemia stage, with stable oral diuretic dosing, stable renal function and optimised therapy. Physiotherapist's mobility data support this decision without replacing it.
Outcome measures
The choice of outcome measures depends of the patient's current stability, its ability to answer a specific clinical question and if it can be repeated. Clinician should always document oxygen, aids, assistance and symptoms during testing.
| Measure | Use | Notes |
|---|---|---|
| Activity Measure for Post-Acute Care (AM-PAC) "6-Clicks"[32] | Early mobility, discharge planning | Quick; predicts discharge destination |
| Borg dyspnoea / RPE | Every session | Primary intensity guide |
| Gait speed (4m)/10m | Function, prognosis | Below 0.8 m/s suggests higher risk |
| 5x Sit-to-Stand | Lower limb strength, falls risk | Easily repeated at the bedside |
| Short Physical Performance Battery (SPPB) | Frailty, mobility | Low scores predict readmission and disability |
| 2MWT / 6MWT | Exercise capacity once stable | MCID roughly 30 m; below ~300 m suggests poorer prognosis |
| Timed Up and Go (TUG) / balance measures | Falls risk | Add when balance concerns arise |
| Clinical Frailty Scale | Risk stratification | Interpret alongside function |
Clinical note: A single measurement is a snapshot. Trends across sessions, combined with symptoms and recovery, are more clinically valuable.
Resources
- Effects of acute phase intensive exercise training in patients with acute decompensated heart failure
- Early Cardiac Rehabilitation for Critically Ill Patients With Acute Decompensated Heart Failure
References
- ↑ Ballena-Caicedo J, Zuzunaga-Montoya FE, Valladolid-Sandoval LA, Bautista Zuta JC, Valladares-Garrido MJ, Gutierrez De Carrillo CI, León-Figueroa DA, Vera-Ponce VJ. Global heart failure incidence rate: an updated systematic review and meta-analysis. Frontiers in Cardiovascular Medicine. 2026 Mar 20;13:1714070.
- ↑ Hessel FP. Overview of the socio-economic consequences of heart failure. Cardiovasc Diagn Ther. 2021 Feb;11(1):254-262.
- ↑ Sindone AP, Abhayaratna WP, Chan A, Leung M, Hopper I, Amerena J, De Pasquale CG, Burdeniuk C, Coats AJ, Atherton JJ. Heart failure with preserved ejection fraction in patients with obesity: a growing cardiometabolic concern. Heart, Lung and Circulation. 2025 Sep 12.
- ↑ Lan T, Liao YH, Zhang J, Yang ZP, Xu GS, Zhu L, Fan DM. Mortality and Readmission Rates After Heart Failure: A Systematic Review and Meta-Analysis. Ther Clin Risk Manag. 2021 Dec 7;17:1307-1320.
- ↑ Schwinger RHG. Pathophysiology of heart failure. Cardiovasc Diagn Ther. 2021 Feb;11(1):263-276.
- ↑ Naidu AS, Chioncel O, Bruno J, Butler J, Coats AJ, Collins SP, Cotter G, Davison B, Fatima Z, Geavlete O, Girerd N. Precipitants of acute heart failure: a state-of-the-art review from an international expert group. Cardiac Failure Review. 2026 Aug 21;12:e24.
- ↑ 7.0 7.1 Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart Failure With Reduced Ejection Fraction: A Review. JAMA. 2020 Aug 4;324(5):488-504.
- ↑ Memon M, Qadeer Y, Virk HUH, Rizwan A, Coomar PP, Alam M, Khawaja M, Rivera MR, Tang WHW, Krittanawong C. Heart failure with mildly reduced ejection fraction (HFmrEF): where are we now? Heart Fail Rev. 2026 Jul 10;31(1):82.
- ↑ 9.0 9.1 Packer M, Butler J, Ho JE, Lam CS, Petrie MC, Schiattarella GG, Vaduganathan M, Zannad F, Borlaug BA. What are heart failure with preserved ejection fraction mimics, and what are they mimicking? Insights into our conceptualisation of heart failure with preserved ejection fraction as a disease. Journal of Cardiac Failure. 2026 Aug;32(8):1475-81.
- ↑ Kodur N, Tang WW. Management of heart failure with improved ejection fraction: current evidence and controversies. Heart Failure. 2025 Apr 1;13(4):537-53.
- ↑ Classes and Stages of Heart Failure. Available from https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure [last accessed 15.11.2026]
- ↑ Jasińska-Gniadzik K, Szwed P, Gasecka A, Zawadka M, Grabowski M, Pietrasik A. Haemodynamic monitoring in acute heart failure–what you need to know. Advances in Interventional Cardiology / Postępy w kardiologii interwencyjnej. 2022 Apr 1;18(2):90-100.
- ↑ Shah MR, Hasselblad V, Stinnett SS, Gheorghiade M, Swedberg K, Califf RM, O'Connor CM. Hemodynamic profiles of advanced heart failure: association with clinical characteristics and long-term outcomes. J Card Fail. 2001 Jun;7(2):105-13.
- ↑ Pecchia B, Samuel R, Shah V, Newman E, Gibson GT. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction (HFpEF). Heart Fail Rev. 2025 Jul;30(4):777-789.
- ↑ Katz SD. In search of euvolemia in heart failure. JACC: Heart Failure. 2014 Jun;2(3):306-7.
- ↑ Mocan D, Jipa R, Jipa DA, Lala RI, Rasinar FC, Groza I, Sabau R, Sulea Bratu D, Balta DF, Cioban ST, Puschita M. Unveiling the Systemic Impact of Congestion in Heart Failure: A Narrative Review of Multisystem Pathophysiology and Clinical Implications. J Cardiovasc Dev Dis. 2025 Mar 31;12(4):124.
- ↑ Polyzogopoulou E, Bezati S, Karamasis G, Boultadakis A, Parissis J. Early Recognition and Risk Stratification in Cardiogenic Shock: Well Begun Is Half Done. J Clin Med. 2023 Apr 1;12(7):2643.
- ↑ Montalto M, D'Ignazio F, Camilli S, Di Francesco S, Fedele M, Landi F, Gallo A. Heart Failure in Older Patients: An Update. J Clin Med. 2025 Mar 14;14(6):1982.
- ↑ Salah HM, Biegus J, Ponikowski PP, Fudim M. Role of Lymphatics in Heart Failure. J Soc Cardiovasc Angiogr Interv. 2023 Dec 4;2(6Part B):101204.
- ↑ Dunlay SM, Chamberlain AM. Multimorbidity in Older Patients with Cardiovascular Disease. Curr Cardiovasc Risk Rep. 2016 Jan;10:3.
- ↑ Diagnosing Heart Failure. Available form https://www.heart.org/en/health-topics/heart-failure/diagnosing-heart-failure [last accessed 15.11.2026]
- ↑ Harjola VP, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca HP, Chioncel O, Collins SP, Doehner W, Filippatos GS, Flammer AJ, Fuhrmann V, Lainscak M, Lassus J, Legrand M, Masip J, Mueller C, Papp Z, Parissis J, Platz E, Rudiger A, Ruschitzka F, Schäfer A, Seferovic PM, Skouri H, Yilmaz MB, Mebazaa A. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017 Jul;19(7):821-836.
- ↑ Allen LA, O'Connor CM. Management of acute decompensated heart failure. CMAJ. 2007 Mar 13;176(6):797-805.
- ↑ George J, Wilson Tang WH. Evolving Decongestion Strategies in the Management of Acute Heart Failure. Curr Treat Options Cardiovasc Med. 2025;27(1):71.
- ↑ Byrne E, Blunt A, Churchill L, Dass S, Grant K, McCleary K, Nickels M, O’Connor L, Picard L, Raatz B, Schonfeldt-Roy S. MOVIN in ICU: An observational study of Mobilisation On Vasopressors and INotropes in intensive care. Heart & Lung. 2026 May 1;77:102751.
- ↑ Haennel RG. Exercise rehabilitation for chronic heart failure patients with cardiac device implants. Cardiopulm Phys Ther J. 2012 Sep;23(3):23-8.
- ↑ Lee JH, Hwang KK. End-of-Life Care for End-stage Heart Failure Patients. Korean Circ J. 2022 Sep;52(9):659-679.
- ↑ 28.0 28.1 Kakutani N, Fukushima A, Kinugawa S, Yokota T, Oikawa T, Nishikawa M, Nakamura R, Tsukada T, Mori S, Yoshida I, Anzai T. Progressive Mobilization Program for Patients With Acute Heart Failure Reduces Hospital Stay and Improves Clinical Outcome. Circ Rep. 2019 Feb 19;1(3):123-130.
- ↑ Kagaya Y, Okura K, Minakata S, Echigoya K, Abe Y, Shioya T. SHORT-TERM INSPIRATORY MUSCLE TRAINING IN HOSPITALIZED HEART FAILURE PATIENTS IS SAFE AND EFFECTIVE FOR IMPROVING INSPIRATORY MUSCLE STRENGTH AND DYSPNOEA ON EXERTION. In RESPIROLOGY 2018 Nov 1 (Vol. 23, pp. 318-318). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.
- ↑ Whitlock K. Acute Decompensated Heart Failure. Plus course 2026
- ↑ Jaarsma T, Hill L, Bayes-Genis A, La Rocca HB, Castiello T, Čelutkienė J, Marques-Sule E, Plymen CM, Piper SE, Riegel B, Rutten FH, Ben Gal T, Bauersachs J, Coats AJS, Chioncel O, Lopatin Y, Lund LH, Lainscak M, Moura B, Mullens W, Piepoli MF, Rosano G, Seferovic P, Strömberg A. Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021 Jan;23(1):157-174.
- ↑ Jette DU, Stilphen M, Ranganathan VK, Passek SD, Frost FS, Jette AM. AM-PAC "6-Clicks" functional assessment scores predict acute care hospital discharge destination. Phys Ther. 2014 Sep;94(9):1252-61.